**Background of TGFBR3 Antibodies**
TGFBR3 (transforming growth factor-beta receptor type III), also known as betaglycan, is a co-receptor for TGF-β superfamily ligands, including TGF-β, activins, and bone morphogenetic proteins (BMPs). Unlike TGFBR1 and TGFBR2. it lacks intrinsic kinase activity but modulates signaling by presenting ligands to their signaling receptors or sequestering them. TGFBR3 plays dual roles in cancer, acting as a tumor suppressor in some contexts (e.g., breast, prostate) or promoting metastasis in others (e.g., glioblastoma, melanoma), depending on cellular and microenvironmental factors.
TGFBR3 antibodies are essential tools for studying its expression, localization, and function. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate TGF-β signaling dysregulation in diseases such as fibrosis, cardiovascular disorders, and cancer. These antibodies help identify TGFBR3’s role as a potential biomarker for prognosis or therapeutic response. Challenges include ensuring specificity, as TGFBR3 undergoes proteolytic cleavage and exists in soluble or membrane-bound forms. Commercial antibodies are often validated against specific isoforms or epitopes to minimize cross-reactivity. Recent research also explores TGFBR3-targeted therapies, such as blocking ligand-receptor interactions in cancer. Overall, TGFBR3 antibodies remain critical for unraveling TGF-β pathway complexity and its translational applications.